PDF(Sci-hub)
Abstract：
Despite the recent introduction of new drugs, castration-resistant metastatic prostate cancer, (mCRPC) remains a poor prognosis disease, with a crucial need for new therapeutic approaches. Tasquinimod is a newly developed molecule, orally administered, currently evaluated in phase III studies. Tasquinimod targets the tumor microenvironment, focusing on the angiogenic and immune components. Its specific action on the S100A9 protein restores immunity and reduces angiogenesis. A phase II double-blind randomized study against placebo showed an improvement of more than 50% of progression free survival in the group of mCRPC patients treated with tasquinimod, as compared to the placebo group. At a dose of 1mg/day, the tolerance of tasquinimod appeared acceptable. This review presents the available preclinical and clinical results of tasquinimod, with a particular focus on the originality of its mode of action.
摘要：
尽管最近推出了新药，去势抵抗性转移性前列腺癌,（mCRPC）仍然是一种预后较差的疾病，迫切需要新的治疗方法。Tasquinimod是一种新开发的分子,口服,目前在III期研究中评估。Tasquinimod靶向肿瘤微环境，专注于血管生成和免疫成分。其对S100A9蛋白的特异性作用可恢复免疫力并减少血管生成。一项针对安慰剂的II期双盲随机研究显示，在接受他喹莫德治疗的mCRPC患者组中，无进展生存期的改善超过50％，与安慰剂组相比。在1mg/天的剂量下，tasquinimod的耐受性似乎可以接受。这篇综述介绍了他喹莫德的可用临床前和临床结果，特别关注其行动模式的独创性。
